[The use of immunomodulator likopid in the combined treatment pulmonary tuberculosis].

Abstract

Licopid is a synthetic analogue of a cell wall component of all bacteria. The monocytic macrophageal system is the main target of licopid's action. Addition of the immunomodulator to combined therapy for patients with pulmonary tuberculosis in order to enhance phagocytic activity exerted a marked clinical effect appeared as ceased bacterial isolation in 80% of the patients, a fall in the amount of purulent sputum, no symptoms of intoxication following 2-3 weeks, accelerated resolution of infiltrative changes. The positive clinical effect coincided with the immunological one manifested as increases in the absolute counts of CD3+CD4+ and CD3+CD8+ cells, in the absorptive and bactericidal functions of phagocytes. Such effects were not observed in patients receiving routine treatment. Licopid is recommended for supplementation to the combined treatment regimen for pulmonary tuberculosis.

• Authors: A S Svistunova, B V Pinegin, R P Selitskaia, S S Arshinova, E G Klimova, T M Andronova, F A Batyrov, A V Simonova
• Journal: Problemy tuberkuleza (Probl Tuberk) Issue 3 Pg. 21-5 ( 2002) ISSN: 0032-9533 [Print] Russia (Federation)
• Vernacular Title: Primenenie immunomoduliatora likopida v kompleksnom lechenii tuberkuleza legkikh.
• PMID: 12066527 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• glikopin
• Acetylmuramyl-Alanyl-Isoglutamine

Topics

• Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives, therapeutic use)
• Adjuvants, Immunologic (therapeutic use)
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Combined Modality Therapy
• Female
• Humans
• Male
• Middle Aged
• Tuberculosis, Pulmonary (drug therapy)